Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase

Cdc25A and Cdc25B dual-specificity phosphatases are key regulators of cell cycle transition and proliferation. They have oncogenic properties and are overexpressed in many human tumors. Because selective Cdc25 phosphatase inhibitors would be valuable biological tools and possible therapeutic agents, we have assayed a small molecule library for in vitro inhibition of Cdc25. We now report the identification of two new structurally distinct classes of Cdc25 inhibitors with cellular activity. The cyclopentaquinoline 3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4,8-dicarboxylic acid (5661118) and the naphthofurandione 3-benzoyl-naphtho[1,2-b]furan-4,5-dione (5169131) had in vitro IC50 values of 2.5 to 11 μM against recombinant Cdc25 and were less potent inhibitors of other phosphatases. Unlike 5661118, 5169131 caused reversible inhibition of Cdc25B and displayed competitive inhibitor kinetics. No growth inhibitory activity was seen with 5661118, whereas 10 to 30 μM 5169131 caused G1/S and G2/M arrest. We also found that 5169131 inhibited human PC-3 prostate and MDA-MB-435 breast cancer cell proliferation. Concentration-dependent Tyr15 hyperphosphorylation was seen on cyclin-dependent kinase with a 1-h 5169131 treatment, consistent with Cdc25 inhibition. Cells resistant to DNA toposiomerase II inhibitors were as sensitive to 5169131 as parental cells, indicating that this quinone compound does not inhibit topoisomerase II in vivo. Molecular modeling was used to predict a potential interaction site between the inhibitor and Cdc25B and to provide insights as to the molecular origins of the experimental observations. Based on its kinetic profile and cellular activity, we suggest that 5169131 could be an excellent tool for further studies on the cellular roles of Cdc25.

[1]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[2]  J. Lazo,et al.  Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione* , 2002, The Journal of Biological Chemistry.

[3]  J. Dixon,et al.  Form and Function in Protein Dephosphorylation , 1996, Cell.

[4]  K D Watenpaugh,et al.  Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. , 1999, Journal of molecular biology.

[5]  P. Wipf,et al.  Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. , 2001, Journal of medicinal chemistry.

[6]  M Monden,et al.  Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. , 2000, Cancer research.

[7]  L. Liu,et al.  Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. , 2001, Biochemistry.

[8]  P. Wipf,et al.  The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity. , 2002, Molecular cancer therapeutics.

[9]  M. Loda,et al.  Role of the Cdc 25 A phosphatase in human breast cancer , 2000 .

[10]  J. Rudolph,et al.  Dual-specific Cdc25B phosphatase: in search of the catalytic acid. , 2000, Biochemistry.

[11]  A. Liu,et al.  Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. , 1997, Cancer research.

[12]  J. Lazo,et al.  The carcinogen (7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene induces Cdc25B expression in human bronchial and lung cancer cells. , 2003, Cancer research.

[13]  F. Hanaoka,et al.  Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210. , 1997, Bioorganic & medicinal chemistry.

[14]  M. Pirrung,et al.  Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. , 2003, Journal of medicinal chemistry.

[15]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[16]  J. Lazo,et al.  Expression in Human Bronchial and Lung Cancer Cells 1 , 2003 .

[17]  P. Wipf,et al.  Dual-specificity phosphatases as targets for antineoplastic agents , 2002, Nature Reviews Drug Discovery.

[18]  W. Allan,et al.  Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. , 1994, British Journal of Cancer.

[19]  Peter Wipf,et al.  Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. , 2002, Molecular pharmacology.

[20]  J. Lazo,et al.  Dual G1 and G2 phase inhibition by a novel, selective Cdc25 inhibitor 6-chloro-7-[corrected](2-morpholin-4-ylethylamino)-quinoline-5,8-dione. , 2002, The Journal of biological chemistry.

[21]  V. Baldin,et al.  A novel synthetic inhibitor of CDC25 phosphatases: BN82002. , 2004, Cancer research.

[22]  E. Fauman,et al.  Crystal Structure of the Catalytic Domain of the Human Cell Cycle Control Phosphatase, Cdc25A , 1998, Cell.

[23]  D. Beach,et al.  Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.

[24]  P. Vaglio,et al.  Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. , 2003, Molecular biology of the cell.

[25]  E. Karsenti,et al.  Activation of the phosphatase activity of human cdc25A by a cdk2‐cyclin E dependent phosphorylation at the G1/S transition. , 1994, The EMBO journal.

[26]  P. Wipf,et al.  Disruption of Insulin-Like Growth Factor-1 Signaling and Down-Regulation of Cdc2 by SC-ααδ9, a Novel Small Molecule Antisignaling Agent Identified in a Targeted Array Library , 1998 .

[27]  M. Loda,et al.  CDC25 phosphatases as potential human oncogenes. , 1995, Science.

[28]  Jiri Bartek,et al.  Regulation of G2/M events by Cdc25A through phosphorylation‐dependent modulation of its stability , 2002, The EMBO journal.

[29]  I. Hoffmann,et al.  Cell cycle regulation by the Cdc25 phosphatase family. , 2000, Progress in cell cycle research.

[30]  M. Gabrielsen,et al.  Distinct Binding Determinants for ERK2/p38α and JNK MAP Kinases Mediate Catalytic Activation and Substrate Selectivity of MAP Kinase Phosphatase-1* 210 , 2001, The Journal of Biological Chemistry.